Wealth Enhancement Advisory Services
BCRX icon

Wealth Enhancement Advisory Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$209K Sell
25,208
-39,941
-61% -$376K ﹤0.01% 3706
2026
Q2 		$681K Buy
65,149
+52,827
+429% +$478K ﹤0.01% 2402
2026
Q1 		$111K Sell
12,322
-3,696
-23% -$28.7K ﹤0.01% 3297
2025
Q4 		$121K Sell
16,018
-5,806
-27% -$42K ﹤0.01% 3393
2025
Q3 		$152K Sell
21,824
-15,942
-42% -$133K ﹤0.01% 3230
2025
Q2 		$338K Buy
37,766
+95
+0.3% +$885 ﹤0.01% 2551
2025
Q1 		$283K Buy
37,671
+20,043
+114% +$162K ﹤0.01% 2489
2024
Q4 		$133K Buy
17,628
+284
+2% +$2.16K ﹤0.01% 2762
2024
Q3 		$132K Buy
17,344
+5,340
+44% +$40.6K ﹤0.01% 2510
2024
Q2 		$74.2K Buy
12,004
+743
+7% +$4.1K ﹤0.01% 2435
2024
Q1 		$57.2K Buy
+11,261
New +$63.3K ﹤0.01% 2335
2023
Q4 		– Sell
-12,554
Closed -$88.9K – 2349
2023
Q3 		$88.9K Buy
+12,554
New +$90.2K ﹤0.01% 2112

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
RF
RHS Financial San Francisco, California $296M AUM 17.24% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Wealth Enhancement Advisory Services's BCRX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its BioCryst Pharmaceuticals (BCRX) stake by 61% in Q3 2026, selling an estimated $376K and leaving 25,208 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #3706.

Wealth Enhancement Advisory Services first reported a position in BCRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $681K in Q2 2026. 11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Wealth Enhancement Advisory Services held 25,208 shares of BioCryst Pharmaceuticals worth $209K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 39,941 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $376K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3706 holding.
  • Wealth Enhancement Advisory Services first reported a position in BioCryst Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's BioCryst Pharmaceuticals position peaked at $681K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.